2024-520014-22-00招募中3 期
A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator’s Choice of Non-platinum Chemotherapy in Participants with Pretreated Locally Advanced/Metastatic Urothelial Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 265
- 试验地点
- 69
- 主要终点
- Overall Survival (OS)
研究概览
简要总结
- To compare sacituzumab tirumotecan to investigator’s choice nonplatinum chemotherapy with respect to OS
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Has histologically documented locally advanced/metastatic urothelial cancer. Locally advanced disease must not be amenable to resection or radiation with curative intent per investigator assessment.
- •If human immunodeficiency virus (HIV) positive, has well-controlled HIV on antiretroviral therapy (ART).
- •If hepatitis B surface antigen (HBsAg) positive, has received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and has undetectable HBV viral load.
- •If history of hepatitis C virus (HCV) infection, has undetectable HCV viral load.
- •Has adequate organ function.
- •Has measurable disease per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as assessed by the investigator.
- •Has received treatment with anti-programmed cell death [ligand] 1 (anti-PD-[L]1) therapy, platinum-based chemotherapy, and enfortumab vedotin (EV).
- •Prior therapy with disitamab vedotin (DV) is allowed but will not meet the requirement for prior treatment with EV, except in China, where participants may have received DV instead of EV before study entry.
- •Has received a maximum of 3 prior lines of therapy.
- •Has experienced radiographic disease progression on or after the immediate prior line of therapy before study entry.
- •Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days of randomization.
- •Is eligible to receive at least one of the control arm nonplatinum chemotherapy options (paclitaxel, docetaxel, or vinflunine).
- •Is able to provide archival tumor tissue sample or newly obtained biopsy of a tumor lesion not previously irradiated.
排除标准
- •Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing.
- •Has received prior chemotherapy for urothelial cancer with any of the study therapies in the control arm (paclitaxel, docetaxel, and vinflunine).
- •Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.
- •Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.
- •Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
- •Has a current or past history of central nervous system (CNS) metastases and/or carcinomatous meningitis.
- •Has an active infection requiring systemic therapy other than those permitted per protocol.
- •Has a history of stem cell/solid organ transplant.
- •Has not adequately recovered from major surgery, or has ongoing surgical complications.
- •Has uncontrolled, significant cardiovascular disease or cerebrovascular disease.
- •Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
- •HIV-infected participants with a history of Kaposi’s sarcoma and/or Multicentric Castleman’s Disease.
- •Has received prior systemic anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) and has not recovered to grade ≤ 1 or baseline from adverse event (AE) associated with anticancer therapy.
- •Has received prior therapy with trophoblast cell-surface antigen 2 (TROP2)-targeted antibody drug conjugate (ADC).
- •Has received prior therapy with a topoisomerase 1 inhibitor-containing ADC.
- •Has completed prior external radiotherapy within 6 weeks or stereotactic radiotherapy within 4 weeks of start of study intervention, or has radiation related toxicities, requiring corticosteroids.
- •Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
研究组 & 干预措施
MK-2870, MK-2870
Test
干预措施: MK-2870 (Drug)
VINFLUNINE
Comparator
干预措施: VINFLUNINE (Drug)
DOCETAXEL
Comparator
干预措施: DOCETAXEL (Drug)
PACLITAXEL
Comparator
干预措施: PACLITAXEL (Drug)
结局指标
主要结局
Overall Survival (OS)
Overall Survival (OS)
次要结局
- Change From Baseline in EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score
- Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score
- Change From Baseline in EORTC QLQ-C30 Fatigue (Items 10, 12, and 18) Combined Score
- Progression-Free Survival (PFS)
- Objective Response Rate (ORR)
- Duration of Response (DOR)
- Number of Participants Who Experience an Adverse Event (AE)
- Number of Participants Who Discontinue Study Treatment Due to an AE
- Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Combined Score
- Change From Baseline in EORTC QLQ-C30 Nausea/Vomiting (Items 14 and 15) Combined Score
- Change From Baseline in EORTC QLQ-C30 Diarrhea (Item 17) Score
研究者
Abhishek Bavle
Scientific
Merck Sharp & Dohme LLC
研究点 (69)
Loading locations...
相似试验
招募中
3 期
Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and ImmunotherapyRecurrent or Persistent Endometrial Cancer2024-511957-23-00Gilead Sciences Inc.179
招募中
3 期
A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022)2023-508015-23-00Merck Sharp & Dohme LLC5
尚未招募
2 期
A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Subsequent Treatments for Advanced Thymic Epithelial TumorsNCT07343453Sun Yat-sen University38
招募中
2 期
Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerNon-Small Cell Lung CancerNCT07329322Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.30
招募中
不适用
Sac-TMT vs Non-platinum Chemo for la/mUCUrothelial CarcinomajRCT205126002030